MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1111/bju.13578

Медицинская библиотека · BJU international · 2016

Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.

Debruyne Frans M J, Behre Hermann M, Roehrborn Claus G, Maggi Mario, Wu Frederick C W, Schröder Fritz H, Jones Thomas Hugh, Porst Hartmut, Hackett Geoffrey, Wheaton Olivia A, Martin-Morales Antonio, Meuleman Eric, Cunningham Glenn R, Divan Hozefa A, Rosen Raymond C, RHYME Investigators

Сравнительное исследованиеСтатьяМногоцентровое исследованиеПеревод в очереди

Аннотация

OBJECTIVES

To evaluate the effects of testosterone-replacement therapy (TRT) on prostate health indicators in hypogonadal men, including rates of prostate cancer diagnoses, changes in prostate-specific antigen (PSA) levels and lower urinary tract symptoms (LUTS) over time.

PATIENTS AND

METHODS

The Registry of Hypogonadism in Men (RHYME) is a multi-national patient registry of treated and untreated, newly-diagnosed hypogonadal men (n = 999). Follow-up assessments were performed at 3-6, 12, 24, and 36 months. Baseline and follow-up data collection included medical history, physical examination, blood sampling, and patient questionnaires. Prostate biopsies underwent blinded independent adjudication for the presence and severity of prostate cancer; PSA and testosterone levels were measured via local and central laboratory assays; and LUTS severity was assessed via the International Prostate Symptom Score (IPSS). Incidence rates per 100 000 person-years were calculated. Longitudinal mixed models were used to assess effects of testosterone on PSA levels and IPSS.

RESULTS

Of the 999 men with clinically diagnosed hypogonadism (HG), 750 (75%) initiated TRT, contributing 23 900 person-months of exposure. The mean testosterone levels increased from 8.3 to 15.4 nmol/L in treated men, compared to only a slight increase from 9.4 to 11.3 nmol/L in untreated men. In all, 55 biopsies were performed for suspected prostate cancer, and 12 non-cancer related biopsies were performed for other reasons. Overall, the proportion of positive biopsies was nearly identical in men on TRT (37.5%) compared to those not on TRT (37.0%) over the course of the study. There were no differences in PSA levels, total IPSS, or the IPSS obstructive sub-scale score by TRT status. Lower IPSS irritative sub-scale scores were reported in treated compared to untreated men.

CONCLUSIONS

Results support prostate safety of TRT in newly diagnosed men with HG.

Для цитирования: Debruyne Frans M J, Behre Hermann M, Roehrborn Claus G, Maggi Mario, Wu Frederick C W, Schröder Fritz H, Jones Thomas Hugh, Porst Hartmut, Hackett Geoffrey, Wheaton Olivia A, Martin-Morales Antonio, Meuleman Eric, Cunningham Glenn R, Divan Hozefa A, Rosen Raymond C, RHYME Investigators. Testosterone treatment is not associated with increased risk of prostate cancer or worsening of lower urinary tract symptoms: prostate health outcomes in the Registry of Hypogonadism in Men.. BJU international. 2016. DOI: 10.1111/bju.13578.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.